Loading…
Loading…
BLGO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for BLGO and 80,000+ other tickers.
See exactly how BLGO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BLGO and 80,000+ other tickers.
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable…
Former U.S. EPA senior executive Sally Gutierrez will represent BioLargo at the investor event. WESTMINSTER, CA / ACCESS Newswire / August 25, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences company, today announced that it will participate in Gabelli Funds' 4th Annual PFAS Symposium on September 24, 2026, in New York City.
PALM BEACH, Fla., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Gabelli is hosting its 4th Annual PFAS Symposium on September 24th, 2026, in New York City.
Consumer Products Relaunch Set for October Under a Company-Owned Model; Clyra Medical Scaling Ahead of a Second Product Launch; Company to Host Stockholder Town Hall on September 10, 2026 WESTMINSTER, CA / ACCESS Newswire / August 17, 2026 / BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, today announced that it has filed its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2026, and that it will host a stockholder town hall on Thursday, September 10, 2026, at 1:00 p.m. Pacific Time.
The patented AEC removes more than 99% of PFAS chemicals in water, consistently exceeding state and federal requirements, and generates a fraction of the waste of conventional methods. WESTMINSTER, CA / ACCESS Newswire / August 3, 2026 / BioLargo, Inc. (OTCQX:BLGO), an environmental engineering company developing and commercializing sustainable technologies, today announced that its patented Aqueous Electrostatic Concentrator (AEC) has treated more than two million gallons of PFAS-contaminated water in over six months of sustained commercial service at the municipal drinking water facility in Lake Stockholm, New Jersey.
Company to contribute commercial PFAS treatment expertise alongside leading universities, regulators, utilities, and industry organizations advancing next-generation PFAS solutions. WESTMINSTER, CA / ACCESS Newswire / July 30, 2026 / BioLargo, Inc. (OTCQX:BLGO), a cleantech and life sciences innovator and engineering services and solution provider, announced that it has joined the New Jersey PFAS Partnership Innovation Consortium (NJ PFAS-PIC), an NJIT-led initiative focused on accelerating the development, validation, and deployment of PFAS technologies.